EPO (Erythropoietin)

产品名称：EPO (Erythropoietin) ELISA
产    地：Demeditec 
产品货号：DE3646
产品规格：96 Tests
产品说明：
Special remarks: Erythropoietin (EPO) is a heavily glycosylated protein with a molecular weight of about 30,000 - 34,000 Daltons.  Human EPO is a polypeptide consisting of 165 amino acids, containing one O?linked and three N?linked carbohydrate chains. The recombinant EPO is a good substitute for the native protein for use in an immunoassay.  Serum EPO levels are dependent on the rate of production and the rate of clearance of the protein.  Ninety percent of EPO is produced in the peritubular cells of the ***** kidney in response to a decrease in tissue oxygenation. There is evidence indicating that the protein on these cells which detects oxygen saturation of the blood is a heme-containing moiety. As the pO2 of the plasma, a function of the hematocrit decreases, EPO concentration will increase. There are also observations suggesting that normally there is an inverse correlation between serum EPO levels and red blood cell mass.
Quantitation of serum erythropoietin concentration serves as a diagnostic adjunct in determining the cause of anemia or erythrocytosis.  Aplastic anemia, hemolytic anemia and anemia due to iron deficiency all result in serum EPO elevation.  Whereas, EPO levels in patients with secondary anemia due to renal failure and other disorders such as acquired immune deficiency syndrome (AIDS) are generally inappropriately low for the degree of anemia. This is mostly likely caused by an impaired ability of the diseased kidney to produce adequate quantities of EPO. Low concentrations of EPO may give an early warning of kidney transplant rejection. EPO also can be used to monitor AIDS patients undergoing Zidovudine (AZT) therapy.  An increased concentration of EPO verifies that anemia associated with AZT therapy is due to red cell hypoplasia or apliasia.
Polycythemia rubra vera, or primary erythrocytosis (an increase of red blood cell mass) results from unstimulated over production of erythrocytes.  Hence, the increase in the hemoglobin causes decreased production of EPO, which results in subnormal levels of serum EPO.  Secondary polycythemias, which are also characterized by an increase in the total red blood cell mass, occur as a physiological response to elevated levels of circulatory EPO caused by tissue hypoxia.  The hypoxia may be due to such factors as pulmonary fibrosis, cardiovascular disease, prolonged exposure to high altitude, abnormal forms of hemoglobin or drug treatment. Some tumors produce EPO and, in these cases, EPO may be used as a tumor marker to monitor the effectiveness of treatment.
上海玉博生物技术有限公司在为生命科学领域提供丰富的产品与信息资源方面处于国内**地位，公司提供的产品涵盖了二十多个国家近五十万种产品，而且产品的数量与信息在不断的增长和更新，公司提供的产品能够使生命科学工作者加快对生物化学，分子生物学，细胞生物学以及蛋白质组学研究的认知，以及分子诊断和临床医学领域的应用。

产品留言

标题

联系人

联系电话

内容

验证码

点击换一张

注：1.可以使用快捷键Alt+S或Ctrl+Enter发送信息!
2.如有必要,请您留下您的详细联系方式!